New Jersey Opioid Antidote Prescription Bill

Focusing on Solutions to the Opioid Crisis, Foundation for Opioid Response Efforts (FORE) Announces Family- and Community-Based Initiatives to Prevent Substance Use Disorder and Overdose

Retrieved on: 
Tuesday, July 20, 2021
Psychoactive drugs, Opioid epidemic, Opioid use disorder, Opioid, Opioid epidemic in the United States, Opioid antagonists, New Jersey Opioid Antidote Prescription Bill

These children are at greater risk of themselves developing a substance use disorder later in life.

Key Points: 
  • These children are at greater risk of themselves developing a substance use disorder later in life.
  • The Foundation for Opioid Response Efforts (FORE) was founded in 2018 as a private 501(c)(3) national, grant-making foundation focused on addressing the nations opioid crisis.
  • FORE is committed to funding a diversity of projects contributing solutions to the crisis at national, state, and community levels.
  • FOREs mission is to support partners advancing patient-centered, innovative, evidence-based solutions impacting people experiencing opioid use disorder, their families, and their communities.

Opioid Overdose Deaths and Relapse are Preventable, The Science Already Exists, Frontline Report Affirms

Retrieved on: 
Thursday, May 6, 2021
Drugs, Psychoactive drugs, Opioids, Medical emergencies, Morphinans, Morphine, Substance-related disorders, Naloxone, Drug overdose, Opioid overdose, Heroin, New Jersey Opioid Antidote Prescription Bill

A Mosaic of Loss & How To Stem Opioid Relapse and Drug Overdose Deaths is both an elegy to the 87,000 Americans who died of an overdose last year, and an educational resource for lay people about evidence-based addiction treatment, relapse prevention, and overdose reversal.\nThe number of opioid overdose deaths in 2020 is staggering, the highest since the early 1990s.

Key Points: 
  • A Mosaic of Loss & How To Stem Opioid Relapse and Drug Overdose Deaths is both an elegy to the 87,000 Americans who died of an overdose last year, and an educational resource for lay people about evidence-based addiction treatment, relapse prevention, and overdose reversal.\nThe number of opioid overdose deaths in 2020 is staggering, the highest since the early 1990s.
  • It was common for people to ingest 1 to 3 grams of heroin daily, without overdosing or dying.
  • Naloxone, the overdose reversal medication, restores and normalizes breathing and heart rate, if given in time.
  • We need to raise public awareness of Medication-Assisted Treatment and overdose reversal medication," Hamburg said.\nTo read or download the report, please visit https://nldetox.com/mosaic-of-loss-opioid-relapse-overdose/\nTo learn more about New Leaf Detox & Treatment, please visit www.nldetox.com\n'

Foundation for Opioid Response Efforts (FORE) Announces Grants Totaling $1.3 Million to Assess Impact of COVID-19 on Opioid Use Disorder Treatment and Equity

Retrieved on: 
Tuesday, March 16, 2021
Psychoactive drugs, Substance dependence, Medical emergencies, Substance abuse, Opioid epidemic, Opioid, Drug overdose, Articles, Opioid epidemic in the United States, New Jersey Opioid Antidote Prescription Bill

The Foundation for Opioid Response Efforts (FORE) today announced it is providing grants totaling $1.3 million to six organizations to assess theimpact of these temporary measures and inform future policies to improve access and promote equity for the treatment of opioid use disorder.

Key Points: 
  • The Foundation for Opioid Response Efforts (FORE) today announced it is providing grants totaling $1.3 million to six organizations to assess theimpact of these temporary measures and inform future policies to improve access and promote equity for the treatment of opioid use disorder.
  • Opioid related overdoses and deaths continue to be one of the nation's leading public health crisis.
  • The project will look at the impact of temporary COVID-19 policies on opioid use disorder treatment, workforce morale, and patient outcomes.
  • The Foundation for Opioid Response Efforts (FORE) was founded in 2018 as a private 501(c)(3) national, grant-making foundation focused on addressing the nation's opioid crisis.

Opioid Prescriptions for Common Orthopaedic Procedures Lack Consistency

Retrieved on: 
Wednesday, March 3, 2021
Psychoactive drugs, Morphine, Analgesics, Opioids, Drugs, Euphoriants, Morphinans, Heroin, New Jersey Opioid Antidote Prescription Bill

These regional and national variations in opioid prescribing practices can serve as a benchmark for orthopaedic surgeons to help develop guidelines to reduce excess postoperative opioid prescriptions.

Key Points: 
  • These regional and national variations in opioid prescribing practices can serve as a benchmark for orthopaedic surgeons to help develop guidelines to reduce excess postoperative opioid prescriptions.
  • They identified a total of 73,921 opioid-naive patients grouped by region (Northeast, South, Midwest and West) who underwent 10 of the most common orthopaedic procedures including:
    The team converted opioid prescriptions related to the surgery to oral morphine equivalents (OME) providing a baseline equivalent for the various opioid types and strengths prescribed to these patients.
  • They analyzed the interquartile ranges (IQR)the range between the 25th percentile and 75th percentilefor the various regions for initial postoperative prescriptions and 90-day total prescriptions for patients undergoing the selected procedures.
  • iiOverton HN, Hanna MN, Bruhn WE, Hutfless S, Bicket MC, Makary MA; Opioids After Surgery Workgroup: Opioid- prescribing guidelines for common surgical procedures: An expert panel consensus.

Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate

Retrieved on: 
Wednesday, February 17, 2021
Drugs, Psychoactive drugs, Morphinans, Medical emergencies, Morphine, Opioids, Ketones, Naloxone, Drug overdose, Heroin, Opioid epidemic in the United States, New Jersey Opioid Antidote Prescription Bill

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHIhigh dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.

Key Points: 
  • SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation(Nasdaq: ADMP) ("Company") today announced that it recently received a notice that one of its patent applications relating to its ZIMHIhigh dose naloxone injection product candidate, intended for the treatment of opioid overdose, was allowed by the U.S. Patent and Trademark Office.
  • The company believes this patent should protect and strengthen the existing intellectual property associated with the product candidate.
  • Concomitant with the rise of overdoses caused by synthetic opioids, deaths have risen despite increased availability of the current naloxone product.
  • Adamis naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review.

NJ Opioid Prevention Measure On Track To Become US Law

Retrieved on: 
Thursday, July 23, 2020
Psychoactive drugs, Opioids, Morphine, Drugs, RTT, Euphoriants, Opioid epidemic in the United States, Sackler family, Heroin, Addiction, Co-prescribing naloxone with opioids, New Jersey Opioid Antidote Prescription Bill

MILLBURN, N.J., July 23, 2020 /PRNewswire/ --The United States House of Representatives is expected to consider a New Jersey-originated legislative initiative to help combat the nationwide opioid crisis.

Key Points: 
  • MILLBURN, N.J., July 23, 2020 /PRNewswire/ --The United States House of Representatives is expected to consider a New Jersey-originated legislative initiative to help combat the nationwide opioid crisis.
  • is planning to introduce legislation based on the Patient Notification Act , passed in New Jersey in 2017.
  • Prior to the enactment of the law, only 18 percent of participants warned patients about the risk of addiction when prescribing opioids.
  • After the law was passed, 95 percent routinely warned patients about the risk of addiction.